No products in the cart.
Pre-made Efdamrofusp Alfa benchmark antibody (Bispecific, anti-C3/CO3;C4B;VEGFA therapeutic antibody, Anti-AHUS5/ARMD9/ASP/CPAMD1/HEL-S-62p;CH/C4F/CO4/C4BD/C4B12/CPAMD3;VPF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-813
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Efdamrofusp Alfa benchmark antibody (Bispecific, anti-C3/CO3;C4B;VEGFA therapeutic antibody, Anti-AHUS5/ARMD9/ASP/CPAMD1/HEL-S-62p;CH/C4F/CO4/C4BD/C4B12/CPAMD3;VPF/MVCD1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
VEGFR1/VEGFR2 fragments-IgG1 Fc-CR1 fusion protein: human
vascular endothelial growth factor receptor 1 (VEGFR1) (104-204)-
peptide (containing the Ig-like C2-type domain 2) (1-101) / human
vascular endothelial growth factor receptor 2 (VEGFR2) (206-308)-
peptide (containing the Ig-like C2-type domain 3) (102-204) / human
immunoglobulin G1 heavy chain constant region C-terminal 227-peptide
fragment (IgG1 Fc) (205-431) [human IGHG1*01; hinge: 205-
214; CH2: 215-324; CH3: 325-429; CHS: 430-431] / G6 peptide linker
(432-437) / human complement receptor type 1 (CR1) [N29>K466,
S37>Y474, G79>D516, D109>N546] (1-192)-peptide (438-629) fusion protein,
dimer (210-210′:213-213′)-bisdisulfide, produced in Chinese hamster
ovary (CHO) cells, glycoform alfa
angiogenesis inhibit
| Products Name (INN Index) | Pre-Made Efdamrofusp Alfa P Alfaiosimilar, Bispecific, Anti-C3/CO3;C4B;VEGFA Antibody: Anti-AHUS5/ARMD9/ASP/CPAMD1/HEL-S-62p;CH/C4F/CO4/C4BD/C4B12/CPAMD3;VPF/MVCD1 therapeutic antibody |
|---|---|
| INN Name | efdamrofusp alfa |
| Target | C3 |
| Format | Bispecific |
| Derivation | NA |
| Species Reactivity | NA |
| CH1 Isotype | NA |
| VD LC | NA |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | NA |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | C3,C4B,VEGFA |
| Package |
Previous slide
Next slide
